Changes in Monoamine Levels in BALB/c and 57Bl/6N Mice in Response to Acute Stress with Different Controllability


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

The severity and specificity of CNS disturbances resulting from negative psychoemotional experience are determined by not only genetically determined stress sensitivity, but also epigenetic factors; among the latter, the context of stress exposure, e.g. stress controllability is considered. We examined the effect of controllability factor on behavioral and neurochemical parameters of acute stress in the elevated plus maze test. The situations of controllable and uncontrollable stress were modeled by allowing or restricting mice in their choice for closed arms during testing in the maze. The anxiety level of inbred BALB/c and C57Bl/6N mice was assessed and the levels and monoamine turnover in the medial prefrontal cortex, hippocampus, amygdala, and hypothalamus were measured. It was found that the decrease in stress controllability suppresses explorative activity in mice; the behavioral and neurochemical differences between the two strains are not constant feature and depend on stress controllability; serotoninergic and dopaminerigic neurotransmission in the hypothalamus can be a signal to discriminate stress controllability in the brain.

Sobre autores

K. Kasabov

V. V. Zakusov Research Institute of Pharmacology

Autor responsável pela correspondência
Email: kirkasabov@gmail.com
Rússia, Moscow

D. Shakhovtsev

N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russian Federation

Email: kirkasabov@gmail.com
Rússia, Moscow

N. Malyshev

N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russian Federation

Email: kirkasabov@gmail.com
Rússia, Moscow

M. Konstantinov

N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russian Federation

Email: kirkasabov@gmail.com
Rússia, Moscow

V. Narkevich

V. V. Zakusov Research Institute of Pharmacology

Email: kirkasabov@gmail.com
Rússia, Moscow

V. Kudrin

V. V. Zakusov Research Institute of Pharmacology

Email: kirkasabov@gmail.com
Rússia, Moscow

E. Anderzhanova

V. V. Zakusov Research Institute of Pharmacology; University Hospital Bonn, Clinic of Psychiatry and Psychotherapy

Email: kirkasabov@gmail.com
Rússia, Moscow; Bonn


Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2019

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies